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Abstract
Background—Heart failure with preserved ejection fraction (HFpEF) is associated with 
significant morbidity and mortality but is currently refractory to therapy. Despite limited 
evidence, heart rate reduction has been advocated, on the basis of physiological considerations, 
as a therapeutic strategy in HFpEF. We tested the hypothesis that heart rate reduction improves 
exercise capacity in HFpEF.  
Methods and Results—We conducted a randomised, crossover study comparing selective heart 
rate reduction with the If blocker, ivabradine at 7.5 mg twice daily, versus placebo for 2 weeks 
each in 22 symptomatic patients with HFpEF who had objective evidence of exercise limitation 
(peak oxygen consumption at maximal exercise, VO2 peak, <80% predicted for age and sex). The 
result was compared to 22 similarly treated matched asymptomatic hypertensive volunteers. The 
primary end point was the change in VO2 peak. Secondary outcomes included tissue Doppler 
derived E/e’ at echocardiography, plasma BNP and quality of life scores. Ivabradine significantly 
reduced peak heart rate compared to placebo in the HFpEF (107 vs. 129 bpm, P<0.0001) and 
Hypertensive (127 vs. 145 bpm, P=0.003) cohorts. Ivabradine, when compared to placebo, 
significantly worsened the change in VO2 peak in the HFpEF cohort (-2.1 vs 0.9 mL/kg/min, 
P=0.003) and significantly reduced submaximal exercise capacity, as determined by the oxygen 
uptake efficiency slope. No significant effects on the secondary endpoints were discernable.
Conclusions—Our observations question the value of heart rate reduction, using ivabradine, for 
improving symptoms in a HFpEF population characterised by exercise limitation.
Clinical Trial Registration Information—www.clinicaltrials.gov. Identifier: NCT02354573. 
Key words: heart failure; heart rate; exercise 
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Up to half of all patients with the clinical features of heart failure have preserved left 
ventricular ejection fraction (HFpEF), defined as an EF  50%.1-3 Mortality rates in patients with 
HFpEF are similar to those with reduced EF (HFrEF)1, 2, 4 and largely due to cardiovascular 
death.4, 5 In contrast to HFrEF, despite the increasing prevalence and hospitalization rate,2, 3 there 
are no proven therapies for HFpEF. The failure of multiple investigational therapies to influence 
survival or affect symptoms in HFpEF likely reflects heterogeneous case inclusion (including 
geographic variation in trial recruitment), suboptimal drug administration with regard to dose, 
stage or endophenotype of disease or an incomplete conception of disease pathophysiology.6-9  
HFpEF has been conceptualised, in part, as a disorder of diastolic function, reflecting 
impairments in active relaxation and intrinsic myocardial compliance.10 More broadly, these 
patients have impairments in ventricular-arterial coupling and of contractile function albeit 
insufficient to reduce global left ventricular ejection fraction, and abnormally low skeletal 
muscle O2 extraction.11, 12 Given the critical contribution of diastole to ventricular filling and 
coronary perfusion, reduction of heart rate (HR), with a view to prolonging diastole, especially in 
atrial fibrillation has been advocated as a therapeutic strategy to mitigate symptoms in HFpEF13 
and endorsed by guidelines.14 However, increased HR is the major physiological contributor to 
the rise in cardiac output necessary to meet the metabolic demands of exercise,15 the capacity for 
which is substantially reduced in both HFpEF and HFrEF.16 Mechanistic studies of patients with 
HFpEF subject to exercise stress have implicated chronotropic incompetence as a potential 
contributor to impaired cardiac output (CO) reserve and thereby likely to contribute to the 
exertional dyspnea and effort intolerance characteristic of the syndrome.16-19 Accordingly, we 
sought to test the hypothesis that HR reduction improves exercise tolerance as assessed by peak 
oxygen consumption (VO2 peak).  
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We performed a placebo-controlled, crossover clinical study to evaluate the effects of 
short-term selective heart rate reduction with ivabradine (2 weeks), an inhibitor of the sinoatrial 
pacemaker funny current (If) considered devoid of effects on cardiac contractility,20 on the 
exercise performance of a homogeneous group of subjects with exercise-limited HFpEF. In order 
to substantiate the generalizability of the results and to inform our understanding of mechanisms 
responsible for exercise limitation, we performed a parallel study in a matched asymptomatic 
hypertensive group representing less advanced pathophysiology. 
 
Methods
Detailed methods are included in the Supplement. 
Study Design 
We undertook a prospective, double-blind, placebo-controlled, randomised crossover trial at two 
UK academic hospitals: the John Radcliffe Hospital, Oxford and the Aberdeen Royal Infirmary. 
The study was designed to assess the effect of short-term administration of Ivabradine on VO2 
peak and other parameters of exercise performance in a well-defined cohort of patients with 
HFpEF and a comparator asymptomatic hypertensive group. The study was approved by the 
Ethics Service Committees in Aberdeen and in Oxford (South Central). All participants provided 
written informed consent to study.  
Study patients 
Consensus has not been reached on the optimal method(s) with which to define HFpEF patients, 
however there is broad agreement that these dynamic disturbances during exercise cannot be 
predicted from resting measures of diastolic function.21 For these reasons, our inclusion criteria 
corresponded to those previously used,22 with rigorous cardiopulmonary exercise testing criteria 
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to establish that the patients were objectively limited compared to age- and gender-predicted 
normal values.  
HFpEF was defined according to: the presence of both symptoms and signs of HF and EF 
 50%, a non-dilated left ventricle (LV) and relevant structural heart disease in the form of left 
ventricular hypertrophy (LVH), left atrial (LA) enlargement and/or evidence of diastolic 
dysfunction on echocardiography (mitral inflow E/A ratio, e’ measured at the mitral annulus and 
E/e’ ratio).23 Eligible patients with HFpEF were at least 60 years of age with subjective exercise 
limitation due to breathlessness or fatigue and objective evidence of exercise limitation as a 
measured VO2 peak on cardiopulmonary exercise testing of <80 % predicted for age and sex, with 
an appropriate pattern of gas exchange.24, 25  
Screening and Intervention 
Eligible participants underwent screening assessment by: history taking and physical 
examination, quality of life assessment measured by the Minnesota Living with Heart Failure 
Questionnaire (MLHFQ),26 biochemical blood analysis, 12-lead ECG, transthoracic 
echocardiography, spirometry and cardiopulmonary exercise testing. 
We screened 65 patients for the HFpEF group and selected 34 matched asymptomatic 
hypertensive patients from a hypertension database over a two-year period from December 2011 
through January 2014 (Figure 1). Of these, 30 patients were found eligible to enter the HFpEF 
group and all 34 patients were eligible for the asymptomatic hypertension group. The first 24 
consecutive patients took part in the HFpEF group, of which 2 participants were excluded in the 
final analysis: one patient did not complete the study and dropped out during the second visit and 
the other was excluded due to sub-optimal exercise testing based on a respiratory exchange ratio 
of 0.81 during their second visit. 22 asymptomatic hypertensive patients consented and 
 at University of Aberdeen on October 5, 2015http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.115.017119 
6 
participated in the study and were all included in the final analysis. In line with existing trial 
protocols of ivabradine in HFrEF aiming for a heart rate target of 50-60 beats per minute,27, 28 
eligible participants were randomly assigned using block randomisation to receive either 
ivabradine 7.5 mg twice daily or matching placebo tablets for 2 weeks (period 1). At the end of 
period 1, all screening assessments were repeated; in addition Cardiovascular Magnetic 
Resonance (CMR) imaging was performed in the HFpEF cohort. After a 2-week washout period, 
subjects were then assigned to the alternative treatment arm (placebo or ivabradine) for a further 
2 weeks (period 2). At the end of this, all period 1 assessments were repeated. Participants, 
investigators and outcome assessors were all blinded to treatment allocation. 
Study End Points 
The predefined primary end point was the change in VO2 peak. Secondary end points were 
changes in: Doppler derived E/e’, BNP (Brain natriuretic peptide) levels and quality of life 
assessed by the MLHFQ. 
Statistical Analysis 
For a crossover study design, power calculation indicated that to detect a mean absolute 
difference in VO2 peak of 2.5mL/kg/min (SD of 2.5 mL/kg/min); 22 patients could provide a 
90% power at an overall two sided alpha level of 0.05.  Continuous variables are reported as 
mean±SD. Data sets were evaluated for normality by the Kolmogorov-Smirnov test. 
Comparisons between HFpEF and the asymptomatic hypertensive group were assessed by two-
tailed Student’s t-test. The comparisons between ivabradine and placebo treatments within 
patient groups were assessed by two-tailed paired Student’s t-test. All statistical analyses were 
performed with the use of SPSS Statistics, version 19 (IBM). A P value of 0.05 or less, using a 
two-tailed test, was considered statistically significant. 
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Results
Baseline Clinical Characteristics 
Baseline clinical characteristics of the patients are shown in Table 1. In comparison to the 
hypertensive group, the patients with HFpEF were older (74.6 vs. 66.9 years, P=0.0001), more 
likely to be female (65 percent vs. 23 percent, P= 0.014) and had a lower proportion of 
hypertension (50 percent vs. 100 percent, P=0.0002). Cardiovascular drug therapy was similar 
between groups, but there was a significantly greater use of calcium channel blockers in the 
hypertensive cohort (55 percent vs. 5 percent in the HFpEF cohort, P=0.0006). 3 HFpEF 
patients, but no hypertensive individuals, were taking beta-blockers (P=0.23). All HFpEF 
patients, but none in the hypertension group, scored significantly on the MLHFQ at baseline. 
There were no differences in resting plasma BNP. The baseline echocardiographic characteristics 
of HFpEF patients are shown in supplementary Table 1. 
Response to Exercise 
Cardiopulmonary exercise testing of HFpEF patients at baseline revealed a significantly lower: 
VO2 peak (16.1 vs. 27.0 mL/kg/min, P<0.0001) (despite satisfactory effort indicated by a 
respiratory exchange ratio > 1.0), anaerobic threshold (11.5 vs. 20.6 mL/kg/min, P<0.0001) and 
maximal workload achieved (4.5 vs. 7.7 metabolic equivalents, METS, P<0.0001), compared to 
the hypertensive group, but an increased ventilatory response to exercise, as indicated by a 
higher minute ventilation-carbon dioxide production ratio (VE/VCO2) (Table 2). Despite being 
asymptomatic, the hypertensive cohort had VO2 peak values that were below mean age- and 
gender-predicted normal values (28.0 mL/kg/min). HFpEF patients had marked chronotropic 
dysfunction with lower peak exercise heart rates (129 vs. 145 bpm, P<0.0001).   
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Selective Heart Rate Lowering with Ivabradine in HFpEF Cohort 
Table 3 (and supplementary Table 2) shows the comparison of ivabradine versus placebo on 
resting haemodynamic, cardiac imaging and exercise parameters in the HFpEF cohort. 
Ivabradine reduced mean resting heart rate by 20 beats per minute (77 to 57, P<0.0001) without 
any effect on blood pressure or left ventricular ejection fraction. Similarly, ivabradine treatment 
reduced the chronotropic response to exercise (peak heart rate 129 vs. 107 beats/minute, 
P<0.0001). The heart rate reduction was accompanied by reduced peak oxygen consumption in 
the majority of HFpEF patients (19 patients had a reduction in the VO2 peak), with a diminution 
in the VO2 peak from 15.9 to 14.8 mL/kg/min (P=0.003), without significantly affecting VE/VCO2 
slope or anaerobic threshold. Moreover, a paired comparison of the changes in VO2 peak resulting 
from the 2-week intervention blocks demonstrated a consonant lowering in the ivabradine group 
(-2.1 vs. 0.9 ml/kg/min, P=0.003) (Figure 2). Compared to placebo, ivabradine treatment 
induced small, but significant, increases in transmitral E/A ratio (0.6 vs. 0.65, P=0.026) and 
mean e’ velocity (4.5 vs. 5.4 cm/s, P=0.002), with no effect on the E/e’ ratio, myocardial 
phosphocreatine to adenosine triphosphate ratios or symptomatic status (MLHFQ - Table 3).  
To assess the influence of ivabradine on submaximal exercise performance in patients 
with HFpEF, an analysis of the relationship between oxygen consumption and ventilation, 
defined as the oxygen uptake efficiency slope (OUES), was also undertaken (Supplement Table 
2 and Supplement Figure 1). OUES is a submaximal measure of cardiorespiratory reserve less 
sensitive to exercise duration and has strong prognostic value in HF.29 Compared to placebo, an 
assessment of the OUES at 75% of the duration of exercise identified a significant reduction with 
ivabradine (1834 vs. 1621 [mL/min O2]/[L/min VE], P=0.04). 
Selective Heart Rate Lowering with Ivabradine in Asymptomatic Hypertensive Cohort 
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As with the HFpEF group, administration of ivabradine at 7.5 mg twice daily significantly 
reduced resting heart rate compared to placebo (from 74 to 61 beats/minute, P=0.001). Peak 
exercise heart rate was blunted by ivabradine use (145 vs. 127 beats/minute, P=0.003). 
Ivabradine use was associated with a statistically non-significant reduction in the primary end 
point, VO2 peak (26 vs. 24.5 mL/kg/min, P=0.47) (Table 4 and supplementary Table 3). 
Compared to placebo, ivabradine treatment was associated with a small but significant increase 
in the VE/VCO2 ratio (27.4 vs. 29.2, P=0.004), but did not affect anaerobic threshold or peak 
workload. 
 
Discussion
We undertook a short term, placebo-controlled, randomised cross-over study examining the 
effect of selective heart rate lowering using the If inhibitor, ivabradine, on exercise capacity in a 
well-defined cohort of patients with symptomatic HFpEF. With individuals acting as their own 
controls, we found that two weeks of heart rate reduction using ivabradine at a dose of 7.5mg 
twice daily in patients with HFpEF almost uniformly exacerbated already abnormal exercise 
physiology, resulting in a significant reduction in the primary end point, VO2 peak.  
Consistent with previous reports,16-19 our cohort of HFpEF patients had poor exercise 
tolerance, a significantly impaired peak oxygen uptake, low VO2 at anaerobic threshold, 
increased ventilatory response and a reduction of the chronotropic response to exercise. 
Cognisant of the broader pathogenesis of HFpEF, including prominent defects in skeletal muscle 
metabolism,11, 12 our patients with HFpEF were not diagnosed based on resting diastolic 
dysfunction, but rather on the basis of subjective exercise limitation with normal LV EF and 
absence of significant valvular disease together with objective exercise limitation. In the 
 at University of Aberdeen on October 5, 2015http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.115.017119 
10 
TOPCAT study, of 935 patients with HFpEF, diastolic function was normal in ~ 1/3 of gradable 
participants.30 We too have observed a poor agreement between exercise E/E’, cardiopulmonary 
exercise testing (CPEX) categorisation and current criteria based on resting diastolic function.31 
We and others have found that HFpEF is characterised by dynamic disturbances of LV active 
relaxation during exercise.32-34 Furthermore, plasma BNP is often relatively normal at rest in 
HFpEF, especially those with a raised BMI in whom BNP appears to be suppressed, but rises 
dramatically on exercise (unpublished data).31, 34, 35  
The choice of peak oxygen uptake at maximal exercise (VO2 peak) as the primary end 
point in this study is supported by its objective measurement of cardiac reserve, robust 
correlation with survival36 and the difficulties in obtaining a true maximal oxygen uptake (VO2 
max), which relies on exercise to absolute exhaustion with plateauing of oxygen uptake despite 
continued exercise.29 In common with VO2 max, VO2 peak is effort-dependent and does not provide 
insight into potential differences in submaximal exercise capacity that may be more reflective of 
the levels of exertion which result in symptoms in HF patients. To address this possibility, we 
also evaluated a measure of submaximal cardiopulmonary reserve – the OUES – whose value 
has, unlike VO2, been shown to be relatively independent of exercise duration and an even more 
powerful predictor of prognosis than conventional measures of exercise performance.29 We 
found that ivabradine treatment also significantly reduced submaximal cardiorespiratory reserve 
in HFpEF. Although there was a significant change in certain parameters of exercise capacity, 
ivabradine treatment did not discernibly alter the cardiac energetic status (PCr/ATP ratio) of the 
HFpEF or hypertensive patients.  
In contrast to the class Ia evidence in HFrEF, limited evidence-based treatment options 
exist for the management of HFpEF. Current therapy includes heart rate reduction, a strategy 
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based on physiological observations dating to the late 19th century that, primarily at higher heart 
rates, shortening of the diastolic filling period impairs cardiac filling and results in lower stroke 
volumes.37 The findings from the present study question this widely held approach, indicating 
that even short-term selective heart rate lowering in the presently defined population of HFpEF 
patients acts to impair exercise capacity, not least as the relationship between decreasing heart 
rate and increasing stroke volume is asymmetric. Moreover, the observation that despite 
ameliorating some measures of cardiac filling (e.g. e’), heart rate reduction almost uniformly 
adversely impacts on exercise tolerance, highlights the need for a broader conceptualisation of 
HFpEF as a chronic, complex disorder of integrated cardiovascular reserve rather than a purely 
diastolic disease.11, 12, 16, 38  
Kosmala et al.13 reported increased exercise capacity in patients with HFpEF following 
short-term treatment with ivabradine. The reason(s) underlying the discrepancy with the current 
study are unclear, but may reflect the younger population studied (mean age 67 years) atypical of 
the clinical population seen with HFpEF, shorter duration and lower dose of ivabradine (7 days 
of 2.5-5 mg twice daily resulting in a reduction in resting heart rate of 10 beats/minute) which 
did not appear to affect peak heart rate response to exercise and perhaps study design (non-
crossover). Our patients, being older, at an age more typical of the HFpEF population, with 
advanced chronotropic incompetence and diminished stroke volume reserve (a largely fixed 
stroke volume) were more sensitive to heart rate reduction. 
The present proof-of-concept study was not designed to address whether selective heart 
rate slowing had longer-term effects on survival or hospitalisation. However, the significant and 
consistent reduction in multiple metabolic stress testing parameters linked to mortality in HF, 
including reduced VO2 peak, raised VE/VCO2, 39 low chronotropic response39 and reduced OUES,29 
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suggest the need for caution with indiscriminate heart rate reduction in this population of 
patients. Harmful off-target effects beyond the inhibition of sinoatrial If are possible. Indeed, 
subgroup analyses of SIGNIFY using ivabradine suggested a signal for cardiovascular harm in 
stable coronary artery disease.40 However, we speculate that we are observing mechanism-
related drug effects and that reducing heart rate with other agents (e.g. -adrenergic blockade) 
may confer similar or more profound adverse effects in HFpEF, due to their impact on heart rate 
and exercise dependant ventricular lusitropy.41 
The following represent potential limitations of our study: i) The sample size studied was 
small, but the treatment was not found to be beneficial in either of the two groups. Importantly, 
in this crossover study, we observed no evidence of a carryover or period effects; the washout 
period of 2 weeks (336hrs) exceeds the biological half-life of ivabradine (2hrs). Nevertheless, the 
study needs to be replicated in a larger clinical trial examining a well-defined homogenous 
cohort powered to look at mortality and morbidity end points that may support this and point to 
alternative strategies to improve exercise intolerance.  ii) The heart rate reduction of 20 bpm in 
our study group was greater than previously studied in trials using ivabradine. A beneficial effect 
resulting from a lesser heart rate reduction cannot be excluded.  
In conclusion, the results of the current study do not support a general strategy of heart 
rate reduction in HFpEF and question its role in improving symptoms in these patients.  
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Table 1. Clinical and Demographic Characteristics of the HFpEF and Asymptomatic 
Hypertensive Cohorts at Baseline. 
HFpEF
(n = 22) 
Hypertensive 
(n = 22) p Value 
Age (years) 74.6 ± 5.9 66.9 ± 5.2 0.0001 
Women, n (%) 14 (65) 5 (23) 0.014 
Body mass index (kg/m2) 29.9 ± 6.2 26.7 ± 2.9 0.036 
   NYHA I - 22 (100)  
   NYHA II 22 (100)   
Past medical history, n (%)    
   Hypertension 11 (50) 22 (100) 0 .0002 
   Diabetes 2 (10) 3 (14) 1.0 
   Dyslipidemia 9 (41) 1 (5) 0.009 
Medications, n (%)    
   ACE-I/ARB-II 13 (59) 15 (68) 0.75 
   Beta-blockers 3 (14) 0 0.23 
   Statin 10 (46) 10 (46) 1 
   Calcium blockers 1 (5) 12 (55) 0.0006 
   Diuretics  14 (64) 8 (36) 0.13 
   Oral hypoglycemic agents 1 (5) 0 1 
Biochemical     
   Hemoglobin, g/dL 13.6 ± 1.3 14.2 ± 0.9 0.07 
   Creatinine, μmol/L 81.5 ± 30.4 77.1 ± 13.9 0.56 
   Blood glucose, mmol/L 5.5 ± 0.9 5.5 ± 0.9 0.84 
   Total cholesterol, mmol/L 4.5 ± 0.9 4.5 ± 0.9 0.89 
   BNP, pmol/L 13.4 (7.5-24.4) 16.4 (11.1-31.7) 0.10 
Values are mean ± SD, percentages or median (quartiles 1 to 3). ACE = angiotensin-converting enzyme-inhibitors; 
ARB = angiotensin-receptor antagonist-II; BNP = brain natriuretic peptide. 
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Table 2. Baseline Hemodynamics and Cardiopulmonary Exercise Testing characteristics of 
HFpEF and Asymptomatic Hypertensive Cohort.
HFpEF
(n = 22) 
Hypertensive 
(n = 22) p Value 
Heart rate, beats/min (rest) 75 ± 12 78 ± 14 0.36 
Heart rate, beats/min (peak) 127 ± 19 159 ± 14 < 0.0001 
Systolic BP, mmHg 148 ± 19 147 ± 7 0.91 
Diastolic BP, mmHg  83 ± 6 82 ± 12 0.82 
VO2 peak (mL/kg/min)  16.1 (15.0 – 18.2) 27.0 (22.5 – 31.2) < 0.0001 
Percentage of predicted VO2 max (%) 66 96 0.009 
VE/VCO2 34.4 ± 6.1 27.3 ± 3.4 < 0.0001 
Anaerobic Threshold (mL/kg/min) 11.5 ± 2.4 20.6 ± 4.8 < 0.0001 
RER 1.08 ± 0.08 1.17 ± 0.06 0.0002 
Values are mean ± SD, percentages or median (quartiles 1 to 3).  BP = blood pressure; VE/VCO2, minute ventilation-
carbon dioxide production ratio; RER, respiratory exchange ratio; METS = Metabolic Equivalents. 
Table 3. Effect of Ivabradine versus Placebo on Cardiac imaging and Exercise Parameters in the 
HFpEF Cohort
Placebo
(n = 22) 
Ivabradine
(n = 22) p Value 
Change in VO2 peak (mL/kg/min) during 
each arm of treatment 
0.9 (-0.6 – 2.1) -2.1 (-2.9 – 0) 0.003 
VO2 peak (mL/kg/min) 15.9 (14.9 - 18.4) 14.8 (13 – 17.4) 0.003 
LV ejection fraction (%) 64.4 ± 8 66.6 ± 4.5 0.23 
e’ (mean of septal and lateral), cm/s 4.5 ± 1.1 5.4 ± 1.5 0.002 
E/e’ ratio 10.4 ± 2.5 10.7 ± 2.4 0.56 
MLHFQ 20.6  ± 16.1 21.7 ± 16.9 0.55 
Values are mean ± SD, percentages or median (quartiles 1 to 3).  LV = left ventricular; e’ = peak early diastolic 
mitral annular velocity; MRI = Magnetic Resonance Imaging; MRS = Magnetic Resonance Spectroscopy, PCr/ATP 
ratio = Phosphocreatine-to-ATP ratio. 
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Table 4. Effect of Ivabradine versus Placebo on Cardiac Imaging and Exercise Parameters in the 
Asymptomatic Hypertensive Cohort 
Placebo
(n = 22) 
Ivabradine
(n = 22) p Value 
Change in VO2 peak (mL/kg/min) during each 
arm of treatment 
1 (-1 – 4) -1.5 (-5.3 – 1) 0.08 
VO2 peak (mL/kg/min) 26 (21 – 29) 24.5 (21.5 – 29.5) 0.47 
LV ejection fraction (%) 65.9 ± 9.3 67.7 ± 9.3 0.43 
e’ (mean of septal and lateral), cm/s 7.2 ± 1.9 8.2 ± 2.2 0.12 
E/e’ ratio 10.6 ± 3.6 11.2 ± 4.5 0.61 
MLHFQ 0 (0 - 0.3) 0 (0 – 0) 1 
Values are mean ± SD, percentages or median (quartiles 1 to 3).  BP = blood pressure; LV = left ventricular; e’ = 
peak early diastolic mitral annular velocity; MRI = Magnetic Resonance Imaging; MRS = Magnetic Resonance 
Spectroscopy, PCr/ATP ratio = Phosphocreatine-to-ATP ratio. 

Figure Legends: 
Figure 1. Flow diagram of the Study. 
Figure 2. Effect of Ivabradine on VO2 peak in HFpEF cohort. Depicts the change in VO2 peak 
(mL/kg/min) with Placebo (left) and Ivabradine (right) (Ivabradine vs placebo P=0.003), in the 
HFpEF cohort.
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SUPPLEMENTAL MATERIAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUPPLEMENTAL METHODS 
Resting transthoracic echocardiography was undertaken using a Philips iE33 system (Philips 
Medical Systems, The Netherlands) in accordance with ESC guidelines.1 Diastolic 
evaluation was in accordance with joint recommendations of the European Association and 
American Society of Echocardiography2 and included measurement of peak early (E) and 
late (A) diastolic mitral inflow velocities, the deceleration time of the early filling velocity (DT), 
tissue Doppler mitral annular early (e’) and late (a’) diastolic velocities with subsequent 
calculation of E/e’ (e’ taken as average of septal and lateral annular velocities). All 
measurements were averaged from three consecutive cardiac cycles and images acquired 
by the same experienced sonographer for each subject at every visit. 
Cardiopulmonary exercise testing was undertaken using a symptom-limited erect treadmill or 
bicycle exercise protocol (according to patient suitability) with simultaneous respiratory gas 
analysis, as described.3, 4 All exercise protocols were undertaken on the same platform once 
selected for an individual patient. Direct measurements of oxygen consumption (VO2), 
carbon dioxide production (VCO2) and minute ventilation (VE) were made. An incremental 
protocol was utilised whereby speed and inclination (for treadmill exercise) or resistance and 
speed (for bicycle exercise) were gradually increased every minute during continual blood 
pressure and ECG measurement. Subjects were encouraged to exercise to exhaustion, with 
a corresponding adequate respiratory exchange ratio achieved as a requirement for 
satisfactory effort. Exercise was terminated at subject request due to fatigue or dyspnoea. 
Peak oxygen consumption (VO2 peak) was determined by averaging VO2 measures over 30 
seconds of peak exercise. The oxygen uptake efficiency slope was defined as the regression 
slope (a) of VO2 against VE plotted on a semilogarithmic scale such that VO2 = a log VE + b.
5  
CMR at Oxford was performed on a Siemens 3T Trio MR system (Erlangen, Germany) for 
assessment of cardiac volumes, mass and function from SSFP short-axis stacks using 
Argus post-processing software (Siemens Healthcare, Erlangen, Germany) only in the 
HFpEF cohort. In Aberdeen, a similar protocol was performed on a 1.5 T Philips Intera and 
Achieva systems (Philips Medical Systems, Best, The Netherlands). Cine images were 
acquired using standard Steady State Free Precession (SSFP) imaging. For 31P 
spectroscopy, subjects were placed in the prone position, with the heart approximately 
centred on the middle of a 31P coil. 31P-MR spectroscopy was performed with 3D acquisition-
weighted chemical shift imaging, using ultra-short time (UTE)-CSI. Correction factors for 
saturation and muscle contamination were applied. The area under each resonance is 
proportional to the amount of each 31P nucleus species in the heart, allowing direct 
quantification of the relative concentrations of ATP and phosphocreatine. 
Exclusion criteria for both cohorts included: LV EF < 50%; inability to perform exercise 
testing; inability to tolerate CMR, e.g. due to claustrophobia or inability to lie flat; contra-
indications to CMR, including the presence of implantable devices, internal cardioverter-
defibrillator, cranial aneurysm clip, metallic ocular foreign body or known hypersensitivity to 
gadolinium; the presence of other significant cardiac disease, including ischemic, valvular, 
pericardial disease or cardiomyopathy (hypertrophic, dilated or restrictive); asthma; second 
or third degree atrioventricular block; sick sinus syndrome; atrial fibrillation; significant resting 
bradycardia (heart rate < 60 beats/minute); objective evidence of lung  disease on lung 
function testing; or significant renal impairment (estimated GFR < 30 mL per minute per 1.73 
m2 body surface area). 
The hypertensive patient cohort were aged 60 years of age or older, with no symptoms or 
clinical signs of heart failure, normal LV EF with no significant valvular disease on screening 
echocardiography and no known cardiac or respiratory disease. Subjects were recruited 
prospectively from a large on-going hypertension database. 
 
 
Supplemental Table 1: Baseline Echocardiographic Characteristics of the HFpEF 
Cohort 
 
 
 HFpEF 
(n = 22) 
   
LV ejection fraction (%)  64.5 ± 7.9 
LV end-diastolic volume index (mL/m
2
)  36.4 (30.6 – 42.2) 
LA volume index (mL/m
2
)  28.0 ± 12.3 
LV mass index (g/m
2
)  109.0 ± 25.3 
E/A ratio  0.7 (0.6 – 1.1) 
E wave deceleration time, ms  185 ± 67 
e’ (mean of septal and lateral), cm/s  5.2 ± 1.5 
E/e’ ratio  11.1 ± 2.4 
   
 
Values are mean ± SD, percentages or median (quartiles 1 to 3).  LV = left ventricular; LA = 
left atrial; E = peak early diastolic mitral flow velocity; A = late diastolic mitral flow velocity; e’ 
= peak early diastolic mitral annular velocity. 
 
 
 
 
 
 
Supplemental Table 2:  Effect of Ivabradine versus Placebo on Resting Hemodynamic, 
Cardiac imaging and Exercise Parameters in the HFpEF Cohort 
 
 
Placebo 
(n = 22) 
Ivabradine 
(n = 22) 
   
Heart rate, beats/min (rest) 77 ± 13 57 ± 9 
Heart rate, beats/min (exercise) 129 ± 20 107 ± 18 
Systolic BP, mmHg 142 ± 25 149 ± 28 
Diastolic BP, mmHg  79 ± 12 76 ± 10 
LV end-diastolic volume index (mL/m
2
) 30.3 (26.7 – 40.0) 29.0 (25.8 – 40.0) 
LA volume index (mL/m
2
) 27.0 ± 10.7 31.3 ± 12.2 
LV mass index (g/m
2
) 109.0 ± 29.1 102.0 ± 22.5 
E/A ratio 0.60 (0.50 – 0.70) 0.65 (0.56 – 1.08) 
E wave deceleration time, ms 170 ± 44 177 ± 52 
VE/VCO2 36.1 ± 6.5 36.1 ± 6.1 
Anaerobic Threshold (mL/kg/min) 11.5 ± 2.9 10.4 ± 2.5 
RER 1.1 ± 0.1 1.1 ± 0.1 
OUES 1834 ± 563 1621 ± 347 
MRI LV ejection fraction (%) 74.1 ± 6.4 73.9 ± 7.2 
MRI LV end-diastolic volume index (mL/m
2
) 60.8 ± 11.7 64.8 ± 11.7 
MRI LV end-systolic volume index (mL/m
2
) 16.3 ± 6.7 17.5 ± 7.7 
MRI LV mass index (g/m
2
) 53.7 ± 12.3 52.1 ± 12.4 
MRS PCr/ATP ratio 1.69 ± 0.41 1.68 ± 0.39 
   
 
Values are mean ± SD, percentages or median (quartiles 1 to 3).  BP = blood pressure; LV = 
left ventricular; LA = left atrial; E = peak early diastolic mitral flow velocity; A = late diastolic 
mitral flow velocity; VE/VCO2 = minute ventilation-carbon dioxide production ratio; RER = 
respiratory exchange ratio; OUES = oxygen uptake efficiency slope; MRI = Magnetic 
Resonance Imaging;  
  
Supplemental Table 3: Effect of Ivabradine versus Placebo on Resting Hemodynamic, 
Cardiac Imaging and Exercise Parameters in the Asymptomatic Hypertensive Cohort 
 
 
Placebo 
(n = 22) 
Ivabradine 
(n = 22) 
   
Heart rate, beats/min (rest) 74 ± 14 61 ± 11 
Heart rate, beats/min (exercise) 145 ± 21 127 ± 23 
Systolic BP, mmHg 136 ± 19 144 ± 14 
Diastolic BP, mmHg  83 ± 13 75 ± 13 
LV end-diastolic volume index (mL/m
2
) 40.9 (28.4 – 55.0) 40.6 (34.7 – 58.0) 
LA volume index (mL/m
2
) 34.9 ± 14.1 40 ± 12.7 
LV mass index (g/m
2
) 85.7 ± 26.9 89.7 ± 24.1 
E/A ratio 0.84 ± 0.18 0.93 ± 0.19 
E wave deceleration time, ms 248 ± 56 269 ± 72 
VE/VCO2 27.4 ± 3.4 29.2 ± 3.5 
Anaerobic Threshold (mL/kg/min) 19.7 ± 5.9 19.4 ± 5.6 
RER 1.2 ± 0.1 1.2 ± 0 
OUES 1953 ± 511 1990 ± 447 
MRI LV ejection fraction (%) 65.0 ± 6.6 68.0 ± 7.4 
MRI LV end-diastolic volume index (mL/m
2
) 60.7 ± 20.1 61.6 ± 21.5 
MRI LV end-systolic volume index (mL/m
2
) 24.5 ± 8.3 22.8 ± 8.6 
MRI LV mass index (g/m
2
) 101.0 ± 21.2 107.0 ± 20.3 
MRS PCr/ATP ratio 1.81 ± 0.84 1.49 ± 0.69 
   
Values are mean ± SD, percentages or median (quartiles 1 to 3).  BP = blood pressure; LV = 
left ventricular; LA = left atrial; E = peak early diastolic mitral flow velocity; A = late diastolic 
mitral flow velocity; VE/VCO2, minute ventilation-carbon dioxide production ratio; RER = 
respiratory exchange ratio; OUES = oxygen uptake efficiency slope; MRI = Magnetic 
Resonance Imaging;  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1: Effect of Ivabradine on Selected Parameters of Exercise 
Performance in HFpEF and Asymptomatic Hypertensive Cohort 
 
 
 
 
 
 
 
The figures above depict the change in VO2 peak (mL/kg/min) from Placebo to 
Ivabradine in the HFpEF (left) and Hypertensive (right) cohorts (comparison is made 
between the VO2 peak values at the end of each intervention arm). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
The figures above show the effect of Placebo and Ivabradine on oxygen uptake 
efficiency slope (OUES) in the HFpEF (left) and Hypertensive (right) cohorts. 
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